Systematic review:bevacizumab combined with radiotherapy regimen in NSCLC patients,modulating VEGF/VEGFR2 signaling  

贝伐单抗联合放疗方案通过调节VEGF/VEGFR2信号传导治疗NSCLC患者的系统评价

作　　者：Zhangpeng Song Feng Zhou Yangyong Zhang Jie Zhang Yuan Feng 宋张鹏;周锋;张杨勇;张洁;冯媛(延安大学咸阳医院,陕西咸阳712000;陕西中医药大学第一附属医院,陕西咸阳712000)

机构地区：[1]Xianyang Hospital of Yan’an University,Xianyang 712000,Shaanxi,China [2]The First Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang 712000,Shaanxi,China

出　　处：《Journal of Chinese Pharmaceutical Sciences》2024年第12期1137-1145,共9页中国药学(英文版)

摘　　要：To assess the efficacy of radiotherapy combined with bevacizumab compared to radiotherapy alone in patients with non-small cell lung cancer(NSCLC)and to explore its impact on anti-tumor neovascularization,we conducted a retrospective analysis of 100 NSCLC patients treated in the oncology department of our hospital from January 2020 to January 2021.The control group(n=50)received conservative treatment with chemotherapy,while the observation group(n=50)underwent treatment with bevacizumab combined with radiotherapy.Clinical data were collected from patient records.Levels of vascular endothelial growth factor(VEGF)and its receptors VEGFR1 and VEGFR2 in serum were measured using enzyme-linked immunosorbent assay(ELISA).The therapeutic outcomes of both groups were assessed based on established evaluation criteria.The Lung Cancer Symptom Scale and Lung Cancer Treatment Function were utilized to evaluate patients'quality of life.Patients were followed up for 2 years,and survival rates were analyzed.Our findings revealed that serum levels of VEGF,VEGFR1,and VEGFR2 in the observation group were significantly lower than those in the control group(P<0.05).Additionally,the observation group exhibited higher rates of complete response,partial response,and disease control compared to the control group(P<0.05),along with a lower rate of disease progression(P<0.05).The Lung Cancer Symptom Scale score was lower in the observation group compared to the control group(P<0.05),while the Functional Assessment of Cancer Therapy-Lung(FACT-L)score and Total Outcome Index(TOI)were higher(P<0.05),indicating a superior quality of life in the observation group.At 6 months,there was no significant difference in survival rates between the two groups(P>0.05);however,at 12,18,and 24 months,the observation group demonstrated higher survival rates than the control group(P<0.05).The median survival time of the observation group(20 months)was significantly longer than that of the control group(15 months,P<0.05).In conclusion,the combination of beva探讨贝伐单抗联合放疗与单独使用放疗治疗方案相比对NSCLC患者的疗效以及对抗肿瘤新生血管生成作用的影响,同时评估治疗后NSCLC患者生活质量和预后。回顾性分析2020年1月–2021年1月在我院肿瘤科就诊治疗的100例NSCLC患者为研究对象,对照组(n=50)采用放疗手段进行保守治疗,观察组(n=50)采用贝伐珠单抗联合放疗治疗。根据患者档案统计临床信息,ELISA检测血清VEGF及VEGFR的表达水平。根据疗效评定标准分析两组患者治疗效果。使用肺癌症状量表和肺癌症治疗功能评估衡量贝伐单抗联合放疗对患者生活质量的影响,同时对患者进行两年随访并分析生存率。结果显示观察组血清VEGF、VEGFR1和VEGFR2水平较对照组降低(P<0.05)。观察组完全缓解率、部分缓解率和疾病控制率较对照组升高(P<0.05),观察组疾病进展率较对照组降低(P<0.05)。观察组LCSS评分较对照组降低(P<0.05),观察组FACT-L和综合评分TOI较对照组升高(P<0.05),观察组生活质量较对照组升高(P<0.05)。6个月时,两组患者生存率比较无差异(P>0.05),12个月、18个月和24个月时,观察组生存率较对照组升高(P<0.05)。观察组中位生存期为20个月,对照组中位生存期为15个月,观察组中位生存时间较对照组延长(P<0.05)。研究表明贝伐单抗联合放疗方案可下调NSCLC患者体内VEGF、VEGFR的表达,对抗肿瘤新生血管生成,改善NSCLC患者生存质量,延长生命期限。

关 键 词：one Bevacizumab combined with radiotherapy NSCLC VEGF VEGFR Clinical effect 

分 类 号：R512.91[医药卫生—内科学]